Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company is focused on maintaining a strong balance sheet, with a net debt to equity ratio of 0.38x as of June 2024, reflecting financial strength. Interest costs have decreased quarter-on-quarter due to efforts like reducing working capital borrowings and negotiating better spread rates with lenders. Ongoing CAPEX projects (Rs. 540 crore agro-specialty plant, Rs. 450 crore AHF project, Rs. 288 crore cGMP-4, Rs. 84 crore R32 capacity expansion, and Rs. 30 crore new capab

Any current/future capex/capital investment/strategic investment?

Rs. 540 crore agro-specialty project targeted for commercial production by September FY25; firm purchase orders secured for FY25. Rs. 450 crore AHF project to enhance HF capacity by 40,000 MT at Dahej, on track to commence by end FY25/early FY26. Rs. 288 crore cGMP-4 CAPEX underway, planned commissioning by end of calendar year 2025. Additional R32 CAPEX of Rs. 84 crores to boost capacity by 4,500 tonnes, expected completion by February 2025. Rs. 30 crore CAPEX for new capability development in Surat, progressing for commissioning in Q2 FY25. Plans to upscale capacity to aspirational Rs. 100 m

Future growth expectations in sales/revenue/volumes?

FY25 expected to see recovery in agrochemical demand in the second half after inventory rationalization. Rs. 540 crore agro-specialty CAPEX plant to commence commercial production by September FY25, targeting full capacity utilization and meeting firm purchase orders. FY25 revenues expected to improve with increased capacity utilization and ramp-up of new projects. FY26 anticipated to see better performance than FY25, driven by new capacities coming online. FY27 expected to hit Rs. 100 crore aspirations for CDMO business, with significant capacity expansion completing end of calendar year 2025

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 expected to witness gradual recovery in agrochemicals with demand uptick in second half, aiding revenue growth. CDMO segment to see improvement with increasing late-stage commercial molecules; FY25 better than FY24 anticipated. FY25 operating EBITDA margin improved sequentially (Q1 at 19.2%), with marginal margin expansion planned through the year. Rs. 540 crore agrochemical plant to commission in September FY25, expected to contribute peak revenues by FY27. Capacity expansions (R32, HF, cGMP-4) expected to drive medium-term revenue growth. FY27 target of Rs. 100 crore revenue in CDMO seg

Current/ Expected Orderbook/ Pending Orders?

The Rs. 540 crore agrochemical plant, commissioning in September FY25, has firm, non-cancellable orders from a global major. This order book is part of a mature relationship involving multiple products (4-5) under supply agreements. For FY25, the plant's capacity utilization is expected to be dedicated 50%, fulfilling existing firm orders. Additional campaigns (~100 metric tonnes) will be run to qualify products for future orders. The CDMO business has a strong pipeline; confident that FY25 will be better than FY24. FY27 is targeted to reach the aspiration of $100 million revenue in CDMO, back

Navin Fluo.Intl.Q1 FY25

Navin Fluo.Intl. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,352P/E: 52.5Market Cap: ₹41.8K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

FY25 expected to see recovery in agrochemical demand in the second half after inventory rationalization.
Rs. 540 crore agro-specialty CAPEX plant to commence commercial production by September FY25, targeting full capacity utilization and meeting firm purchase orders.
FY25 revenues expected to improve with increased capacity utilization and ramp-up of new projects.
FY26 anticipated to see better performance than FY25, driven by new capacities coming online.
FY27 expected to hit Rs. 100 crore aspirations for CDMO business, with significant capacity expansion completing end of calendar year 2025.
R32 capacity expansion (additional 4,500 tonnes) on track to complete by February 2025 to meet strong market demand.
Specialty chemical pipeline growing with new molecules expected to contribute incremental Rs. 60-80 crore revenue by 2027.
Overall revenue growth guided by ramp-up of CAPEX projects and improving market conditions, particularly in second half of FY25 onward.

Margin guidance

Category 3

FY25 expected to witness gradual recovery in agrochemicals with demand uptick in second half, aiding revenue growth.
CDMO segment to see improvement with increasing late-stage commercial molecules; FY25 better than FY24 anticipated.
FY25 operating EBITDA margin improved sequentially (Q1 at 19.2%), with marginal margin expansion planned through the year.
Rs. 540 crore agrochemical plant to commission in September FY25, expected to contribute peak revenues by FY27.
Capacity expansions (R32, HF, cGMP-4) expected to drive medium-term revenue growth.
FY27 target of Rs. 100 crore revenue in CDMO segment based on new capacity coming online late calendar 2025.
Continuous cost optimization and R&D investments to protect and improve EBIT and ROCE.
Earnings impacted in short term by higher depreciation and interest costs linked to new CAPEX.
Overall, improving margins and rising capacity utilization expected to support earnings and EPS growth post FY25.

See what Navin Fluo.Intl. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
The company is focused on maintaining a strong balance sheet, with a net debt to equity ratio of 0.38x as of June 2024, reflecting financial strength.
Interest costs have decreased quarter-on-quarter due to efforts like reducing working capital borrowings and negotiating better spread rates with lenders.
Ongoing CAPEX projects (Rs. 540 crore agro-specialty plant, Rs. 450 crore AHF project, Rs. 288 crore cGMP-4, Rs. 84 crore R32 capacity expansion, and Rs. 30 crore new capability in Surat) are advancing as planned, with no mention of raising additional funds for these.
The company emphasizes internal financial discipline and improving cash flow without indicating the need for external fundraising at this time.

Order book

Yes

The Rs. 540 crore agrochemical plant, commissioning in September FY25, has firm, non-cancellable orders from a global major.
This order book is part of a mature relationship involving multiple products (4-5) under supply agreements.
For FY25, the plant's capacity utilization is expected to be dedicated 50%, fulfilling existing firm orders.
Additional campaigns (~100 metric tonnes) will be run to qualify products for future orders.
The CDMO business has a strong pipeline; confident that FY25 will be better than FY24.
FY27 is targeted to reach the aspiration of $100 million revenue in CDMO, backed by capacity expansion coming online end of calendar year 2025 (FY26).
Orderbook visibility in CDMO is improving quarter-on-quarter.
Domestic CDMO supplies happen temporarily until product registrations with global majors are complete; then exports commence directly.
Overall, orderbook is robust, backed by long-term supply contracts and ongoing strong customer relationships.

See what Navin Fluo.Intl. management said on order book — free account, 30 seconds.

Capex plans

Yes

Rs. 540 crore agro-specialty project targeted for commercial production by September FY25; firm purchase orders secured for FY25.
Rs. 450 crore AHF project to enhance HF capacity by 40,000 MT at Dahej, on track to commence by end FY25/early FY26.
Rs. 288 crore cGMP-4 CAPEX underway, planned commissioning by end of calendar year 2025.
Additional R32 CAPEX of Rs. 84 crores to boost capacity by 4,500 tonnes, expected completion by February 2025.
Rs. 30 crore CAPEX for new capability development in Surat, progressing for commissioning in Q2 FY25.
Plans to upscale capacity to aspirational Rs. 100 million in CDMO by FY27, with extra capacity coming on stream late calendar year 2025.
Ongoing upgrades to flexibility at the agro plant to cater to more molecules at customer's cost.

Track Navin Fluo.Intl. — get its next earnings analysis in your feed

How does Navin Fluo.Intl. rank vs peers in ?

Pro feature

ThisNavin Fluo.Intl.

Rev 3Mar 3

See where Navin Fluo.Intl. sits in See which companies these are, and every other name in the sector.Open rankings

What Navin Fluo.Intl.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Navin Fluo.Intl. Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Navin Fluo.Intl.'s management said in earlier quarters